Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ethyl ximeninate is the ethyl ester of ximenynic acid (also known as santalbic acid), a polyunsaturated fatty acid typically derived from the seeds of plants in the *Ximenia* or *Santalum* genera. In topical and cosmetic applications, it is primarily recognized for its ability to stimulate cutaneous microcirculation and provide anti-inflammatory and antioxidant benefits. It acts by inhibiting certain inflammatory pathways and supporting tissue trophy. Currently, it is being investigated as an ingredient in topical emulgels to treat symptoms of vulvovaginal atrophy and female sexual dysfunction in postmenopausal women, where it aims to improve lubrication, reduce inflammation, and enhance mucosal health in combination with other vasodilatory and moisturizing agents.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ethyl ximeninate.